Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Stereotaxis to Highlight Enhanced Technology and Results at HRS 2013 in Denver



Stereotaxis to Highlight Enhanced Technology and Results at HRS 2013 in Denver

ST. LOUIS, May 7, 2013 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
announced that it will highlight the milestones and clinical results achieved
with its cutting-edge Epoch™ platform, as well as preview enhancements to the
Epoch suite, at the 34^th Annual Heart Rhythm Society (HRS) Scientific
Sessions, May 8-11, 2013 in Denver, CO. The Company has surpassed an industry
leading 60,000 procedures on its remote magnetic navigation system, more than
10,000 of which were performed in 2012.

"We are excited to share with the HRS audience how our technologies have
transformed the practice of electrophysiology (EP) for hundreds of physician
users and what is ahead for us in terms of product innovation," says William
Mills, Stereotaxis Board Chairman and interim Chief Executive Officer. "The
safety of our robotic solutions is second to none, and the evidence continues
to grow on other significant clinical and economic benefits. We remain focused
on advancing and refining our magnetic and robotic navigation systems for
optimal performance."

Mr. Mills says the Company's vision is to become the new standard of care in
EP procedures across the globe and has already succeeded in doing so in
countries such as Finland, where all five of its teaching hospitals, who
collectively handle the vast majority of the country's complex EP cases, now
routinely use Stereotaxis innovations.

More than 460 EPs worldwide utilize Stereotaxis technology today. Three of
these physicians will speak to their personal experiences with the Epoch
platform, including the platform's impact on reducing procedure time,
increasing patient volume and other favorable results through in-booth
presentations (Booth 1802) at the following times:

  * May 9, 3:30-4:00 p.m. – Dr. Tamas Szili-Torok, Erasmus Medical Center
  * May 10, 10:00-10:30 a.m. – Dr. William Spear, Advocate Christ Medical
    Center
  * May 10, 10:30-11:00 a.m. – Dr. J. Peter Weiss, Intermountain Medical
    Center

Furthermore, the Robotic EP Society, conceived by Stereotaxis physician users
and other robotic advocates at the 2012 HRS Scientific Sessions, will convene
during the three-day event. The group's purpose is to exchange best practices
and clinical insights, while building a network of experts intent on moving
robotics from early adopters to generalized usage in electrophysiology.

In addition to a growing base of product champions, an increasing number of
peer-reviewed publications – over 200 to date – are illuminating the
advantages of remote magnetic catheter navigation in the treatment of a broad
range of complex arrhythmias. Recently published clinical data include
"Catheter Ablation of Ventricular Tachycardias Using Remote Magnetic
Navigation," Szili-Torok et al (2012), a consecutive case-control study which
demonstrated that the use of magnetic navigation offers significant advantages
for ablation of both non-structural heart disease-VT and structural heart
disease-VT; and "Long-Term Efficacy of Single Procedure Remote Magnetic
Catheter Navigation of Ablation of Ischemic Ventricular Tachycardia," Dinov et
al (2012), which found that magnetic navigation of ischemic sustained VT is
equally effective compared with manual ablation in terms of acute and
long-term success rates.

To further validate the clinical strengths of the Epoch platform, the Company
is launching its first-ever randomized, multi-center study in Europe and has
selected four study sites. HRS participants can discuss additional research
interests at the Company's booth, as well as preview Stereotaxis product
enhancements in development. These innovations come on the heels of several
major advancements to the Epoch suite launched since HRS 2012, including the
new TargetNav and TargetNav Line automation features for magnetic navigation,
the second generation Odyssey® Vision QHD and the V-Sono™^1 ICE catheter
manipulator module for the Vdrive™ platform.

About Stereotaxis           

Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. With over 100
patents for use in a hospital's interventional surgical suite, Stereotaxis
helps physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and productivity, and
enhanced collaboration of life-saving information. Stereotaxis' core Epoch™
Solution includes the Niobe^® ES Remote Magnetic Navigation system, the
Odyssey^® portfolio of lab optimization, networking and patient information
management systems and the Vdrive^™ Robotic Mechanical Navigation system and
consumables. 

The core components of Stereotaxis systems have received regulatory clearance
in the U.S., Europe, Canada and elsewhere. The V-Loop^™ circular catheter
manipulator is currently in clinical trials in order to obtain clearance by
the U.S. Food and Drug Administration; the Company also is pursuing U.S.
clearance for the V-Sono™ ICE catheter manipulator. For more information,
please visit www.stereotaxis.com.

^1Approved in Europe and Canada; U.S. clearance under review

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, our continued access to
capital and financial resources on a timely basis and on terms that are
acceptable, our continued listing on the Nasdaq Global Market, continued
acceptance of the Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to purchase
our systems and the timing of such purchases, the outcome of various
shareholder litigation recently filed against us, competitive factors, changes
resulting from the recently enacted healthcare reform in the U.S., including
changes in government reimbursement procedures, dependence upon third-party
vendors, timing of regulatory approvals, and other risks discussed in the
Company's periodic and other filings with the Securities and Exchange
Commission. By making these forward-looking statements, the Company undertakes
no obligation to update these statements for revisions or changes after the
date of this release. There can be no assurance that the Company will
recognize revenue related to its purchase orders and other commitments in any
particular period or at all because some of these purchase orders and other
commitments are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.

CONTACT: Press Contact:
         Frank Cheng
         Senior Vice President, Marketing and
         Business Development
         314-678-6111
        
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
         323-468-2300
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement